ACE2 and COVID-19: This latter specific effect provides a reasonable explanation for the lack of worse outcomes in COVID-19 patients taking ACE inhibitors/Angiotensin II receptor blockers, which is confirmed by patients with Gitelman and Bartter syndromes—rare genetic tubulopathies, a human model of endogenous antagonism of Ang II signaling via AT1R—who have increased ACE2 and Ang 1–7 [7].